NEW YORK, NY--(Marketwire - June 14, 2012) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 273 practicing urologists who answered within two days on their expected use of PCA3 testing in men suspected of having prostate cancer. A PCA3 test received FDA approval in February of this year and is the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
"Based on the results of our proprietary survey we believe there is strong interest in the use of the test by both academic and community based urologists," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "Almost half (49.6%) of the survey responders intend to test their patients with this assay, 47.4% report that they may use it, and only 4.1% do not expect to use the test. Awareness of the test is high and we received survey responses from the physicians in record time."
DiagnoCure Inc. (TSX: CUR) owns the exclusive worldwide diagnostic rights to the PCA3 marker which predicts the results of repeat biopsies more accurately than traditional PSA serum tests, known to have very high false positive rates. PCA3 identifies patients at risk of prostate cancer following a first prostate biopsy and may help reduce unnecessary repeat prostate biopsies. DiagnoCure receives royalties on worldwide sales of the test.
Dr. McDonald's full Survey Report is available to download at no cost at the LifeSci Advisors website, http://lifesciadvisors.com/marketresearch/
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.